Promising drug targets Hard-to-Treat breast cancer in Early-Stage trial
Disease control
Not yet recruiting
This study tests whether the drug sacituzumab govitecan can slow down advanced triple-negative breast cancer when used as the very first treatment. About 24 adults who have not had prior therapy for their advanced cancer will receive the drug on days 1 and 8 of each 21-day cycle.…
Phase: PHASE2 • Sponsor: Nathalie Levasseur • Aim: Disease control
Last updated May 12, 2026 13:39 UTC